Drug interactions
Lorlatinib + Repotrectinib
Severity: Major
Lorlatinib and Repotrectinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Repotrectinib is metabolized by CYP3A4 and its labeling advises avoiding CYP3A inducers. Lorlatinib may lower repotrectinib exposure and reduce antitumor efficacy.
What this interaction means in plain words
Lorlatinib and Repotrectinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Lorlatinib belongs to Oncology; Repotrectinib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing repotrectinib metabolism.
What to do
Avoid coadministration and select an alternative therapy. If unavoidable, monitor tumor response closely.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Repotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Repotrectinib
- Apalutamide + Repotrectinib Contraindicated
- Amiodarone + Repotrectinib Major
- Amobarbital + Repotrectinib Major
- Aprepitant + Repotrectinib Major
- Armodafinil + Repotrectinib Major
- Bosentan + Repotrectinib Major
Frequently asked questions
Can I take Lorlatinib with Repotrectinib?
MediHelp rates the interaction as major. Lorlatinib and Repotrectinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Repotrectinib is metabolized by CYP3A4 and its labeling advises avoiding CYP3A inducers. Lorlatinib may lower repotrectinib exposure and reduce antitumor efficacy.
How serious is the interaction between Lorlatinib and Repotrectinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid coadministration and select an alternative therapy. If unavoidable, monitor tumor response closely.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
